FATE THERAPEUTICS INC (FATE)
US31189P1021 - Common Stock
Overall FATE gets a fundamental rating of 3 out of 10. We evaluated FATE against 568 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for FATE as it has an excellent financial health rating, but there are worries on the profitability. FATE has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
FATE had negative earnings in the past year.
In the past year FATE has reported a negative cash flow from operations.
In the past 5 years FATE always reported negative net income.
In the past 5 years FATE always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of FATE (-36.01%) is better than 61.42% of its industry peers.
The Return On Equity of FATE (-49.19%) is better than 67.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.01% | ||
| ROE | -49.19% | ||
| ROIC | N/A |
ROA(3y)-31.58%
ROA(5y)-31.01%
ROE(3y)-44.38%
ROE(5y)-43.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
FATE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FATE has more shares outstanding
FATE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -3.56, we must say that FATE is in the distress zone and has some risk of bankruptcy.
FATE's Altman-Z score of -3.56 is in line compared to the rest of the industry. FATE outperforms 45.13% of its industry peers.
There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -3.56 |
ROIC/WACCN/A
WACC11.91%
2.3 Liquidity
FATE has a Current Ratio of 8.29. This indicates that FATE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.29, FATE is doing good in the industry, outperforming 73.63% of the companies in the same industry.
A Quick Ratio of 8.29 indicates that FATE has no problem at all paying its short term obligations.
FATE has a Quick ratio of 8.29. This is in the better half of the industry: FATE outperforms 73.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 8.29 | ||
| Quick Ratio | 8.29 |
3. Growth
3.1 Past
FATE shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.78%.
The Revenue for FATE has decreased by -87.34% in the past year. This is quite bad
Measured over the past years, FATE shows a very strong growth in Revenue. The Revenue has been growing by 68.05% on average per year.
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)-87.34%
Revenue growth 3Y26.44%
Revenue growth 5Y68.05%
Sales Q2Q%58.13%
3.2 Future
The Earnings Per Share is expected to grow by 8.48% on average over the next years. This is quite good.
Based on estimates for the next years, FATE will show a very negative growth in Revenue. The Revenue will decrease by -12.71% on average per year.
EPS Next Y-4.98%
EPS Next 2Y-2.79%
EPS Next 3Y3.55%
EPS Next 5Y8.48%
Revenue Next Year-78.85%
Revenue Next 2Y-75.07%
Revenue Next 3Y-62.54%
Revenue Next 5Y-12.71%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
FATE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FATE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.79%
EPS Next 3Y3.55%
5. Dividend
5.1 Amount
FATE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
FATE THERAPEUTICS INC
NASDAQ:FATE (12/20/2024, 8:08:19 PM)
After market: 1.6802 +0 (+0.01%)1.68
+0.02 (+1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.11%
Inst Owner Change-5.86%
Ins Owners2.14%
Ins Owner Change6.29%
Market Cap191.34M
Analysts73.33
Price Target6.43 (282.74%)
Short Float %10.37%
Short Ratio3.97
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.6%
Min EPS beat(2)9.28%
Max EPS beat(2)31.92%
EPS beat(4)4
Avg EPS beat(4)15.63%
Min EPS beat(4)5.72%
Max EPS beat(4)31.92%
EPS beat(8)8
Avg EPS beat(8)24.68%
EPS beat(12)11
Avg EPS beat(12)18.03%
EPS beat(16)12
Avg EPS beat(16)10.74%
Revenue beat(2)2
Avg Revenue beat(2)249.31%
Min Revenue beat(2)127.37%
Max Revenue beat(2)371.26%
Revenue beat(4)4
Avg Revenue beat(4)142.75%
Min Revenue beat(4)3.08%
Max Revenue beat(4)371.26%
Revenue beat(8)7
Avg Revenue beat(8)102.95%
Revenue beat(12)10
Avg Revenue beat(12)83.9%
Revenue beat(16)14
Avg Revenue beat(16)93.55%
PT rev (1m)-4.09%
PT rev (3m)-5.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.47%
EPS NY rev (1m)0.27%
EPS NY rev (3m)0.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)43.92%
Revenue NY rev (1m)18.86%
Revenue NY rev (3m)18.86%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 14.23 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.53 | ||
| P/tB | 0.53 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.12
BVpS3.18
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.01% | ||
| ROE | -49.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-31.58%
ROA(5y)-31.01%
ROE(3y)-44.38%
ROE(5y)-43.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 4.28% | ||
| Cap/Sales | 6.06% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 8.29 | ||
| Quick Ratio | 8.29 | ||
| Altman-Z | -3.56 |
F-Score2
WACC11.91%
ROIC/WACCN/A
Cap/Depr(3y)386.28%
Cap/Depr(5y)331.25%
Cap/Sales(3y)45.8%
Cap/Sales(5y)44.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y-4.98%
EPS Next 2Y-2.79%
EPS Next 3Y3.55%
EPS Next 5Y8.48%
Revenue 1Y (TTM)-87.34%
Revenue growth 3Y26.44%
Revenue growth 5Y68.05%
Sales Q2Q%58.13%
Revenue Next Year-78.85%
Revenue Next 2Y-75.07%
Revenue Next 3Y-62.54%
Revenue Next 5Y-12.71%
EBIT growth 1Y4.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.61%
EBIT Next 3Y-4.14%
EBIT Next 5YN/A
FCF growth 1Y54.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.82%
OCF growth 3YN/A
OCF growth 5YN/A